LEADER 02006oam  2200421 a 450 
001 9910699942503321
005 20110118113352.0
035   $a(CKB)5470000002406532
035   $a(OCoLC)651817041
035   $a(EXLCZ)995470000002406532
100   $a20100802d2010      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aEnd-stage renal disease$b[electronic resource] $eCMS should monitor access to and quality of dialysis care promptly after implementation of new bundled payment system : report to congressional requesters
210  1$a[Washington D.C.] :$cU.S. Govt. Accountability Office,$d[2010]
215   $a1 online resource (iii, 66 pages) $cillustrations, charts
300   $aTitle from PDF title screen (GAO, viewed July 8, 2010).
300   $a"March 2010."
300   $a"GAO-10-295."
320   $aIncludes bibliographical references.
327   $aLetter--Appendix I objectives, scope, and methodology--Appendix II GAO data collection instrument on dose of dialysis related drugs--Appendix III Medicare expenditures for injectable ESRD drugs by demographic characters--Appendix IV detailed results from data collection instrument on dose of dialysis-related drugs--Appendix V comments from the centers of Medicare & Medicaid services--Appendix VI GAO contact and staff acknowledgments--Tables--Figures.
517   $aEnd-stage renal disease 
606   $aHemodialysis$xPatients$xEconomic aspects
606   $aHemodialysis$xPatients$xMedical care$xGovernment policy$zUnited States
606   $aMedicare$xEconomic aspects
615  0$aHemodialysis$xPatients$xEconomic aspects.
615  0$aHemodialysis$xPatients$xMedical care$xGovernment policy
615  0$aMedicare$xEconomic aspects.
801  0$bVVK
801  1$bVVK
801  2$bGPO
906   $aBOOK
912   $a9910699942503321
996   $aEnd-stage renal disease$93440710
997   $aUNINA